Answers are grounded in this paper and cite their sources.
Experimental findings demonstrate improved neuroprotection in Parkinson's disease with combined pharmacotherapy in rats, highlighting new therapeutic targets.
Conclusions: We have experimentally demonstrated a new target of neuroprotection in PD conditions - apoptosis of dopamine-producing neurons and substantiated modulators of this process - drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran, and gliatilin) as promising drugs for PD treatment.
No takes yet. Share an insight, caveat, or question.
Tyshchenko et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: